JP2020511469A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511469A5
JP2020511469A5 JP2019550688A JP2019550688A JP2020511469A5 JP 2020511469 A5 JP2020511469 A5 JP 2020511469A5 JP 2019550688 A JP2019550688 A JP 2019550688A JP 2019550688 A JP2019550688 A JP 2019550688A JP 2020511469 A5 JP2020511469 A5 JP 2020511469A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
effective amount
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019550688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020511469A (ja
JP7293122B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022462 external-priority patent/WO2018170145A1/en
Publication of JP2020511469A publication Critical patent/JP2020511469A/ja
Publication of JP2020511469A5 publication Critical patent/JP2020511469A5/ja
Priority to JP2023030606A priority Critical patent/JP2023071824A/ja
Application granted granted Critical
Publication of JP7293122B2 publication Critical patent/JP7293122B2/ja
Priority to JP2025014511A priority patent/JP2025072437A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019550688A 2017-03-14 2018-03-14 補体が媒介する疾患および障害を処置するための方法 Active JP7293122B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023030606A JP2023071824A (ja) 2017-03-14 2023-03-01 補体が媒介する疾患および障害を処置するための方法
JP2025014511A JP2025072437A (ja) 2017-03-14 2025-01-31 補体が媒介する疾患および障害を処置するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471190P 2017-03-14 2017-03-14
US62/471,190 2017-03-14
US201762553059P 2017-08-31 2017-08-31
US62/553,059 2017-08-31
PCT/US2018/022462 WO2018170145A1 (en) 2017-03-14 2018-03-14 Methods for treating complement-mediated diseases and disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023030606A Division JP2023071824A (ja) 2017-03-14 2023-03-01 補体が媒介する疾患および障害を処置するための方法

Publications (3)

Publication Number Publication Date
JP2020511469A JP2020511469A (ja) 2020-04-16
JP2020511469A5 true JP2020511469A5 (https=) 2021-04-22
JP7293122B2 JP7293122B2 (ja) 2023-06-19

Family

ID=61873979

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019550688A Active JP7293122B2 (ja) 2017-03-14 2018-03-14 補体が媒介する疾患および障害を処置するための方法
JP2023030606A Pending JP2023071824A (ja) 2017-03-14 2023-03-01 補体が媒介する疾患および障害を処置するための方法
JP2025014511A Pending JP2025072437A (ja) 2017-03-14 2025-01-31 補体が媒介する疾患および障害を処置するための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023030606A Pending JP2023071824A (ja) 2017-03-14 2023-03-01 補体が媒介する疾患および障害を処置するための方法
JP2025014511A Pending JP2025072437A (ja) 2017-03-14 2025-01-31 補体が媒介する疾患および障害を処置するための方法

Country Status (14)

Country Link
US (1) US20210115116A1 (https=)
EP (1) EP3596121A1 (https=)
JP (3) JP7293122B2 (https=)
KR (2) KR20260039796A (https=)
CN (1) CN110753701A (https=)
AU (2) AU2018236267B2 (https=)
BR (1) BR112019018950A2 (https=)
CA (1) CA3055781A1 (https=)
CR (1) CR20190468A (https=)
IL (2) IL325084A (https=)
MX (2) MX2019010994A (https=)
SG (1) SG11201907583TA (https=)
TW (2) TW202513092A (https=)
WO (1) WO2018170145A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3722320A3 (en) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anti-complement c1s antibodies and uses thereof
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
CA2981321A1 (en) 2015-04-06 2016-10-13 True North Therapeutics, Inc. Humanized anti-c1s antibodies and methods of use thereof
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CN113260375B (zh) 2018-12-13 2024-10-01 阿尔金克斯有限公司 针对人补体因子C2b的抗体及使用方法
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
MX2022006334A (es) * 2019-11-26 2022-06-22 Omeros Corp Metodos para tratar y/o prevenir el sindrome de neumonia idiopatica (ips) y/o el sindrome de fuga capilar (cls) y/o el sindrome de injerto (es) y/o la sobrecarga de fluidos (fo) asociados con el trasplante de celulas madre hematopoyeticas.
FI129383B (en) * 2020-06-15 2022-01-31 Faron Pharmaceuticals Oy Stable anti-clever-1 antibody formulation
IL300376A (en) * 2020-08-06 2023-04-01 Bioverativ Usa Inc Inflammatory cytokines and fatigue in subjects with complement-mediated disease
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
CN117769434A (zh) 2021-05-20 2024-03-26 黛安瑟斯医疗运营公司 与C1s结合的抗体和其用途
CN120757653A (zh) 2021-07-13 2025-10-10 迈威(美国)生物治疗有限公司 抗c1s抗体和其用途
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
CA3260415A1 (en) * 2022-06-24 2023-12-28 Bioverativ Usa Inc. METHODS OF TREATMENT FOR COMPLEMENT-MEDICATED DISEASES
WO2024112734A1 (en) 2022-11-21 2024-05-30 Dianthus Therapeutics Opco, Inc. Antibodies that bind to c1s and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
CA2115811A1 (en) 1993-02-17 1994-08-18 Claus Krebber A method for in vivo selection of ligand-binding proteins
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
WO2015084999A1 (en) * 2013-12-06 2015-06-11 True North Therapeutics, Inc. Complement component biomarker assays

Similar Documents

Publication Publication Date Title
JP2020511469A5 (https=)
JP7628996B2 (ja) 改善された血清アルブミン結合剤
US20240124599A1 (en) Anti-bcma heavy chain-only antibodies
US10618976B2 (en) SIRP-α agonist antibody
US11434299B2 (en) Anti-BCMA heavy chain-only antibodies
US20240117046A1 (en) Heavy chain antibodies binding to cd22
JP2018520139A (ja) エクリズマブまたはエクリズマブバリアントでのワクチン接種に従って患者を処置するための方法
JP2026053563A (ja) 補体関連疾患のための融合タンパク質構築物
KR20230021773A (ko) 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도
CN112442123B (zh) 抗cd47的单克隆抗体及其用途
CN111630065A (zh) 抗c5抗体组合及其用途
WO2016210172A1 (en) Methods of treating autoimmune and alloimmune disorders
CN116724236A (zh) 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
JP7158376B2 (ja) インターロイキン－６のヒト受容体に結合することができる抗体またはその抗原結合フラグメント
RU2824402C2 (ru) Конструкции слитого белка для заболевания, связанного с комплементом
WO2025128263A9 (en) Anti-pd-1 monoclonal antibody and methods of preparation thereof
HK40125060A (zh) 用於抗c1q抗体的制剂
NZ749153A9 (en) Anti-c5 antibodies and uses thereof
NZ749153B2 (en) Anti-c5 antibodies and uses thereof
BR112016025319B1 (pt) Anticorpo anti-fcrn isolado, polinucleotídeos, vetor de expressão recombinante, composições e método para detectar fcrn in vitro